Jacobs Levy Equity Management Inc. Lowers Stake in Regeneron Pharmaceuticals, Inc. $REGN

Jacobs Levy Equity Management Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.8% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 747 shares of the biopharmaceutical company’s stock after selling 100 shares during the period. Jacobs Levy Equity Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $474,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in REGN. Pinney & Scofield Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 31 shares during the period. Activest Wealth Management lifted its holdings in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 21 shares in the last quarter. Costello Asset Management INC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $27,000. Finally, Saudi Central Bank acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $27,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $560.00 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,170.58. The firm’s fifty day simple moving average is $564.61 and its 200-day simple moving average is $579.66. The firm has a market capitalization of $59.35 billion, a price-to-earnings ratio of 14.11, a PEG ratio of 1.90 and a beta of 0.35. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same period last year, the business earned $11.56 EPS. The company’s revenue was up 3.6% on a year-over-year basis. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.87%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on REGN. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating on the stock in a report on Monday, June 9th. BMO Capital Markets increased their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a report on Monday, August 4th. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a report on Tuesday, September 2nd. Finally, Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.